Donata Lucci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Donata Lucci has a total of 272 co-authors. Here are the top co-authors by number of shared publications:
Andrea Di Lenarda
Division of Cardiology, Azienda Sanitaria Universitaria Integrata di Trieste, Italy
5 shared publications- Lucio Gonzini
ANMCO Research Center, Florence, Italy
4 shared publications - Aldo Pietro Maggioni
Centro Studi ANMCO—Heart Care Foundation, 50121 Florence, Italy
3 shared publications - Furio Colivicchi
Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy
3 shared publications - Giuseppe De Luca
Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3 shared publications - Luigi Tavazzi
GVM Care & Research, Maria Cecilia Hospital, 48033 Cotignola Ravenna, Italy
3 shared publications
Latest Publications
- Open Access
- 18 May 2023
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 25 (Supplement) , D147
P275 COMBINED NEURO–HUMORAL MODULATION AND OUTCOME IN PATIENTS WITH CHRONIC HEART FAILURE AND MILDLY REDUCED OR PRESERVED EJECTION FRACTION
Drug therapy of patients with chronic heart failure (HF) with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF) remains a challenge. We aimed to assess whether escalating neuro–humoral–modulation (NHM) (renin–angiotensin system inhibitors (RASI), betablockers (BB), mineralocorticoid receptor antagonists (MRA)) was differentially associated with outcome according to phenotype and age groups. Between 1999 and 2018 we recruited in a nationwide cardiology registry 4707 patients (HFmrEF n=2298, HFpEF n=2409) and classified them into 3 age groups: young (<65 years), old (65–79 years), oldest–old (80+ years). We analysed clinical characteristics and 1–year all–cause mortality/cardiovascular hospitalization according to none/single (RASI or BB or MRA), double (RASI+BB or RASI+MRA or BB+MRA), or triple (MRA+RASI+BB) NHM. Overall, approximately half of HFmrEF and HFpEF patients had double–NHM. Among HFmrEF, 25.1% received no/single and 26.7% triple NHM. In the HFpEF group, 36.5% had no/single and 17.9% triple NHM. Older age was associated with a higher prescription of no/single NHM among HFmrEF patients (ptrend=0.001); the reverse was observed among HFpEF patients (ptrend =0.005). Prescription of triple NHM increased over time in both phenotypes (all p for trend<0.0001). Compared to no/single NHM, triple, but not double, NHM was associated with better outcome in both HFmrEF (HR 0.700, 95% CI 0.505–0.969, p=0.032) and HFpEF (HR 0.700, 95% CI 0.499–0.983, p=0.039), with no interaction between NHM and age groups (p=0.58, p=0.80, respectively).
- 18 May 2023
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 25 (Supplement) , D147
Open AccessP275 COMBINED NEURO–HUMORAL MODULATION AND OUTCOME IN PATIENTS WITH CHRONIC HEART FAILURE AND MILDLY REDUCED OR PRESERVED EJECTION FRACTION
Drug therapy of patients with chronic heart failure (HF) with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF) remains a challenge. We aimed to assess whether escalating neuro–humoral–modulation (NHM) (renin–angiotensin system inhibitors (RASI), betablockers (BB), mineralocorticoid receptor antagonists (MRA)) was differentially associated with outcome according to phenotype and age groups. Between 1999 and 2018 we recruited in a nationwide cardiology registry 4707 patients (HFmrEF n=2298, HFpEF n=2409) and classified them into 3 age groups: young (<65 years), old (65–79 years), oldest–old (80+ years). We analysed clinical characteristics and 1–year all–cause mortality/cardiovascular hospitalization according to none/single (RASI or BB or MRA), double (RASI+BB or RASI+MRA or BB+MRA), or triple (MRA+RASI+BB) NHM. Overall, approximately half of HFmrEF and HFpEF patients had double–NHM. Among HFmrEF, 25.1% received no/single and 26.7% triple NHM. In the HFpEF group, 36.5% had no/single and 17.9% triple NHM. Older age was associated with a higher prescription of no/single NHM among HFmrEF patients (ptrend=0.001); the reverse was observed among HFpEF patients (ptrend =0.005). Prescription of triple NHM increased over time in both phenotypes (all p for trend<0.0001). Compared to no/single NHM, triple, but not double, NHM was associated with better outcome in both HFmrEF (HR 0.700, 95% CI 0.505–0.969, p=0.032) and HFpEF (HR 0.700, 95% CI 0.499–0.983, p=0.039), with no interaction between NHM and age groups (p=0.58, p=0.80, respectively).
- Open Access
- 8 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (22) , 6627
Combined Neuro-Humoral Modulation and Outcomes in Patients with Chronic Heart Failure and Mildly Reduced or Preserved Ejection Fraction
Pharmacotherapy of chronic heart failure with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF) remains challenging. We aimed to assess whether combined neuro-humoral modulation (NHM) (renin–angiotensin system inhibitors, betablockers, mineralocorticoid receptor antagonists) was differentially associated with outcome according to phenotype and age groups. Between 1999 and 2018 we recruited in a nationwide cardiology registry 4707 patients (HFmrEF n = 2298, HFpEF n = 2409) from three age groups: trend = 0.001); the reverse was observed among HFpEF (ptrend = 0.005). Triple NHM increased over time in both phenotypes (all p for trend < 0.0001). Compared to no/single NHM, triple, but not double, NHM was associated with better outcomes in both HFmrEF (HR 0.700, 95%CI 0.505–0.969, p = 0.032) and HFpEF (HR 0.700, 95%CI 0.499–0.983, p = 0.039), with no interaction between NHM treatment and age groups (p = 0.58, p = 0.80, respectively). In a cardiology setting, among HF outpatients with EF > 40%, triple NHM treatment increased over time and was associated with better patient outcomes.
- 8 November 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (22) , 6627
Open AccessCombined Neuro-Humoral Modulation and Outcomes in Patients with Chronic Heart Failure and Mildly Reduced or Preserved Ejection Fraction
Pharmacotherapy of chronic heart failure with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF) remains challenging. We aimed to assess whether combined neuro-humoral modulation (NHM) (renin–angiotensin system inhibitors, betablockers, mineralocorticoid receptor antagonists) was differentially associated with outcome according to phenotype and age groups. Between 1999 and 2018 we recruited in a nationwide cardiology registry 4707 patients (HFmrEF n = 2298, HFpEF n = 2409) from three age groups: trend = 0.001); the reverse was observed among HFpEF (ptrend = 0.005). Triple NHM increased over time in both phenotypes (all p for trend < 0.0001). Compared to no/single NHM, triple, but not double, NHM was associated with better outcomes in both HFmrEF (HR 0.700, 95%CI 0.505–0.969, p = 0.032) and HFpEF (HR 0.700, 95%CI 0.499–0.983, p = 0.039), with no interaction between NHM treatment and age groups (p = 0.58, p = 0.80, respectively). In a cardiology setting, among HF outpatients with EF > 40%, triple NHM treatment increased over time and was associated with better patient outcomes.
- 11 January 2022
- Published by S. Karger AG in Cardiology
- Vol. 147 (2) , 133-136
Could the PARIS Risk Scores Be Useful for the Choice of Triple versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention?
Introduction: Current guidelines recommend dual antithrombotic therapy (DAT) for the majority of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and suggest a short course of triple antithrombotic therapy (TAT) for those at very high thrombotic risk (TR) but low bleeding risk (BR). Methods: We analyze if the PARIS ischemic-hemorrhagic scale could be useful for the choice of antithrombotic strategy in patients with acute coronary syndromes and AF treated with coronary stenting enrolled in the prospective, observational, nationwide MATADOR-PCI study. Results: Among the 588 patients discharged alive, a TAT was prescribed in 381 (64.8%) and DAT in 52 (8.8%) patients. According to the PARIS scoring system, 142 (24.2%) were classified as low, 244 (41.5%) as intermediate, and 292 (34.3%) as high TR. In parallel, 87 (14.8%) were categorized in the low, 260 (44.2%) in the intermediate, and 241 (41.0%) in the high-risk stratum for major bleedings. Crossing the various strata of the two PARIS risk scores, the largest group of patients consisted of those at high TR and BR (n = 130, 22%), followed by those at intermediate risk according to both scores (n = 122, 21%). At discharge, TAT was mainly used in patients at intermediate to high BR, while DAT in those at intermediate to high TR but low BR, according to the PARIS score. Conclusion: Our data suggest that some variables associated with increased TR or BR are poorly considered in the daily practice, while the use of PARIS scales could help in the implementation of guidelines’ recommendations.
- 11 January 2022
- Published by S. Karger AG in Cardiology
- Vol. 147 (2) , 133-136
Could the PARIS Risk Scores Be Useful for the Choice of Triple versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention?
Introduction: Current guidelines recommend dual antithrombotic therapy (DAT) for the majority of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and suggest a short course of triple antithrombotic therapy (TAT) for those at very high thrombotic risk (TR) but low bleeding risk (BR). Methods: We analyze if the PARIS ischemic-hemorrhagic scale could be useful for the choice of antithrombotic strategy in patients with acute coronary syndromes and AF treated with coronary stenting enrolled in the prospective, observational, nationwide MATADOR-PCI study. Results: Among the 588 patients discharged alive, a TAT was prescribed in 381 (64.8%) and DAT in 52 (8.8%) patients. According to the PARIS scoring system, 142 (24.2%) were classified as low, 244 (41.5%) as intermediate, and 292 (34.3%) as high TR. In parallel, 87 (14.8%) were categorized in the low, 260 (44.2%) in the intermediate, and 241 (41.0%) in the high-risk stratum for major bleedings. Crossing the various strata of the two PARIS risk scores, the largest group of patients consisted of those at high TR and BR (n = 130, 22%), followed by those at intermediate risk according to both scores (n = 122, 21%). At discharge, TAT was mainly used in patients at intermediate to high BR, while DAT in those at intermediate to high TR but low BR, according to the PARIS score. Conclusion: Our data suggest that some variables associated with increased TR or BR are poorly considered in the daily practice, while the use of PARIS scales could help in the implementation of guidelines’ recommendations.
- 1 December 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 273, 8-14
Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study
- 1 December 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 273, 8-14
Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study
- Open Access
- 12 July 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (7) , e0199770
Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study
Data on contemporary management patterns of angina in patients with stable coronary artery disease (CAD) are scarce. We sought to describe the current presentation, management, and quality of life of stable CAD patients with or without angina, using the data from the START (STable Coronary Artery Diseases RegisTry) study. START was a prospective, observational, nationwide study aimed to evaluate the presentation, management, treatment and quality of life of stable CAD presenting to cardiologists during outpatient visits or discharged from cardiology wards. Among the 5070 consecutive stable CAD patients enrolled in 183 participating centers over a 3-month period, 3714 (73.2%) had no angina and 1356 (26.8%) presented with angina. Patients with angina underwent more frequently coronary angiography (92.7% vs 84.9%; p<0.0001) and other diagnostic imaging procedures compared to those without angina. In addition, patients with angina received more frequently different combinations of first line therapies and angina relief drugs compared to patients without angina. The quality of life, assessed with the EQ 5D-5L questionnaire, did not differ between the two groups, with the exception of the ‘pain or worry’ domain that was higher in patients with compared to those without angina (p<0.0001). Current management and treatment of stable CAD patients with angina is still suboptimal and different compared to those without angina. Our findings highlight the need for disseminating best-practice patterns and improving guidelines adherence for the management of angina even among cardiologists.
- 12 July 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (7) , e0199770
Open AccessCharacteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study
Data on contemporary management patterns of angina in patients with stable coronary artery disease (CAD) are scarce. We sought to describe the current presentation, management, and quality of life of stable CAD patients with or without angina, using the data from the START (STable Coronary Artery Diseases RegisTry) study. START was a prospective, observational, nationwide study aimed to evaluate the presentation, management, treatment and quality of life of stable CAD presenting to cardiologists during outpatient visits or discharged from cardiology wards. Among the 5070 consecutive stable CAD patients enrolled in 183 participating centers over a 3-month period, 3714 (73.2%) had no angina and 1356 (26.8%) presented with angina. Patients with angina underwent more frequently coronary angiography (92.7% vs 84.9%; p<0.0001) and other diagnostic imaging procedures compared to those without angina. In addition, patients with angina received more frequently different combinations of first line therapies and angina relief drugs compared to patients without angina. The quality of life, assessed with the EQ 5D-5L questionnaire, did not differ between the two groups, with the exception of the ‘pain or worry’ domain that was higher in patients with compared to those without angina (p<0.0001). Current management and treatment of stable CAD patients with angina is still suboptimal and different compared to those without angina. Our findings highlight the need for disseminating best-practice patterns and improving guidelines adherence for the management of angina even among cardiologists.
- 1 December 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 248, 369-375
Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation
- 1 December 2017
- Published by Elsevier in International Journal of Cardiology
- Vol. 248, 369-375
Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation
- 1 October 2011
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29 (10) , 1994-2003
Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study
Background An inappropriately high left ventricular mass (iLVM) may be detected in patients with diabetes mellitus. Several hemodynamic and nonhemodynamic factors stimulating LVM growth may actively operate in these patients. In this study, we assessed prevalence and factors associated with iLVM in patients with diabetes mellitus. Methods We analyzed baseline data from 708 patients (61 ± 7 years, 57% treated for hypertension) with type 2 diabetes mellitus without evidence of cardiac disease enrolled in the left ventricular dysfunction in diabetes study. iLVM was diagnosed by Doppler echocardiography as LVM more than 28% of the expected LVM predicted from height, sex and stroke work. Results iLVM was detected in 166 patients (23%), irrespective of concomitant hypertension. Patients with iLVM were more frequently women, had higher BMI and prevalence of metabolic syndrome, higher serum triglyceride levels and were treated more frequently with metformin and diuretics. In a multivariate model, female sex [odds ratio (OR) 1.502 (95% confidence interval (CI) 1.010–2.231), P = 0.04], higher serum triglyceride levels [OR 1.007 (95% CI 1.003–1.012), P < 0.001] and BMI [OR 1.220 (95% CI 1.116–1.335), P < 0.001] emerged independently related to iLVM. Conclusion iLVM is detectable in about a quarter of patients with type 2 diabetes mellitus without evidence of cardiac disease and is unrelated to blood pressure levels. The association between LVM and some components of metabolic syndrome in these patients may have important practical implications.
- 1 October 2011
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29 (10) , 1994-2003
Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study
Background An inappropriately high left ventricular mass (iLVM) may be detected in patients with diabetes mellitus. Several hemodynamic and nonhemodynamic factors stimulating LVM growth may actively operate in these patients. In this study, we assessed prevalence and factors associated with iLVM in patients with diabetes mellitus. Methods We analyzed baseline data from 708 patients (61 ± 7 years, 57% treated for hypertension) with type 2 diabetes mellitus without evidence of cardiac disease enrolled in the left ventricular dysfunction in diabetes study. iLVM was diagnosed by Doppler echocardiography as LVM more than 28% of the expected LVM predicted from height, sex and stroke work. Results iLVM was detected in 166 patients (23%), irrespective of concomitant hypertension. Patients with iLVM were more frequently women, had higher BMI and prevalence of metabolic syndrome, higher serum triglyceride levels and were treated more frequently with metformin and diuretics. In a multivariate model, female sex [odds ratio (OR) 1.502 (95% confidence interval (CI) 1.010–2.231), P = 0.04], higher serum triglyceride levels [OR 1.007 (95% CI 1.003–1.012), P < 0.001] and BMI [OR 1.220 (95% CI 1.116–1.335), P < 0.001] emerged independently related to iLVM. Conclusion iLVM is detectable in about a quarter of patients with type 2 diabetes mellitus without evidence of cardiac disease and is unrelated to blood pressure levels. The association between LVM and some components of metabolic syndrome in these patients may have important practical implications.